BridgeBio Pharma (BBIO) focuses on rare genetic diseases and has two approved therapies, Attruby and Nulibry, with Attruby accounting for 71% of third-quarter revenue. The article lists three upcoming FDA milestones: a PDUFA date of Nov. 27 for BBP-418, Feb. 4 for oral infigratinib and May 8 for encaleret. Third-quarter total revenue reached $353.2 million, up 193% year over year, including $253.2 million of U.S. net product revenue for Attruby, while the EPS loss narrowed to $0.42 from $0.95. The company reported more than $1.5 billion in cash, nearly 3 times the year-ago level, after closing a $1 billion preferred equity financing. The article acknowledges risks tied to small patient populations but presents three reasons to consider the stock.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Open a keyword to see other news on the same topic.
Related news
- Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
Biotech and healthcare stocks outperformed the broader market in the week ended Oct. 23, with XBI up 3.6%, IBB up 2.9% and XLV up 1.5%, while SPY fell 0.4%. Oruka Therapeutics (ORKA) is set to report 16-week results from its Phase 2b Everlast-B trial of Orka-001 in plaque psoriasis on Monday, and Summit Therapeutics (SMMT) reported Harmoni-GI1 data showing ivonescimab plus chemotherapy cut the risk of death by 25% versus durvalumab plus chemotherapy in advanced biliary tract cancer. The week’s calendar also includes earnings from Novartis, Eli Lilly, Merck, GSK and others, plus FDA target dates, including Inovio’s INO-3107 on Friday. ESMO Congress continues through Tuesday in Madrid, with updates from Incyte and Iovance.
- 1 Reason Compass Pathways Is Worth a Second Look This Month
Compass Pathways (CMPS) is developing COMP360, a synthetic psilocybin for treatment-resistant depression, and plans to complete its FDA application by the end of the year, which could set up an approval decision in early 2027. After positive results in two Phase 3 trials, the FDA awarded COMP360 a Commissioner's National Priority Voucher (CNPV), which could shorten the review period to one or two months after filing. In 52-week results from the COMP005 trial, 40% to 45% of patients in the open-label extension saw at least a 50% reduction in depression symptoms, and about 30% achieved remission. With shares trading around $12, the average analyst price target of $23.75 implies about 95% upside. The article notes that approval is not guaranteed and that commercial adoption will depend partly on insurance reimbursement and the availability of treatment centers.
- Why This Hair Restoration Biotech's Shares Are Soaring
Veradermics (MANE) shares are up 268% since the company’s February 4 IPO, driven by positive phase 3 data for VDPHL01, an extended-release oral minoxidil. In the trial, 78.8% of patients on the daily dose and 85% on the twice-daily dose reported improved hair coverage, versus 35.3% on placebo. If approved, it would be the first oral minoxidil approved by the FDA and an alternative to finasteride, though the company has not given a timeline for its New Drug Application. The company estimates the pattern hair loss market will be worth more than $30 billion by 2028 and reported $820 million in cash as of Q2, enough to fund operations into 2030. The company has no revenue, and the average analyst price target is $170.
- Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Exelixis shares have risen 49% this year, but the FDA has extended the review of zanzalintinib, its investigational colorectal cancer drug, with a decision now expected by March 3, 2027, instead of December 3, 2026. The article argues the outlook remains attractive, citing three factors. First, Cabometyx, its main revenue driver, posted second-quarter revenue up 10.6% year over year to $628.7 million, and patent protection should keep generics out of the U.S. until at least 2030. Second, some analysts estimate zanzalintinib could generate $4.5 billion in U.S. sales by 2033, compared with $2.3 billion in revenue last year. Third, Exelixis has several other early-stage candidates and research collaborations in its pipeline.
- Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics presented new data on lorundrostat at ASN Kidney Week 2026 in Denver, Colorado, from the Phase 3 Launch-HTN trial. Systolic blood pressure reductions were similar in participants with and without CKD across Stages 1-3. At week 12, lorundrostat reduced placebo-adjusted systolic blood pressure by 9.6 mmHg in participants with CKD and 12.2 mmHg in those without. In participants with CKD and baseline albuminuria, the urine albumin-to-creatinine ratio fell 52.2% versus placebo. The drug is under FDA review for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026.
- New bipartisan bill aims to speed up clinical trials for rare disease treatments
Bipartisan Reps. Jake Auchincloss (D) and Morgan Griffith (R) introduced the "Faster Clinical Trials Act" to speed up studies of rare disease treatments, one week after the FDA unveiled a new initiative for these drugs. The bill would create a network of reusable clinical trial sites and a "Center for Clinical Trial Innovation" at the FDA, with up to $75 million in annual funding over five years. Its goal is to cut trial costs and enrollment time by at least 30%, and to let patients receive experimental drugs at their regular doctor's office, with progress tracked through Zoom, electronic health records or wearables. Griffith said this would also help patients who live hours away from medical centers.
Related markets
Latest news
- Strategy Resumes Bitcoin Buys With $66M Purchase
Strategy bought 811 BTC for $65.5 million between October 26 and November 1, resuming purchases after a one-week pause, according to an SEC filing. It also spent $208.2 million from its USD Cash balance to repurchase 2,092,035 STRC shares, cutting USD Cash to $132.7 million from $242.4 million a week earlier. The company now holds 849,327 BTC, acquired for $64.08 billion at an average of about $75,451 per coin. Mizuho kept its Outperform rating and $165 price target on MSTR, while analyst Dan Dolev flagged dilution concerns as Bitcoin per share fell 3.7% this year. Strategy also faces possible removal from MSCI's equity indexes, with the list of affected companies due on November 11.
- Apple has turned into Wall Street's hedge against the AI trade: Chart of the Day
Apple has moved against chip stocks, rising on 30 of the 46 days the Philadelphia Semiconductor Index fell 2% or more, a much higher share than in past years. Its correlation with the chip index turned negative in July and hit a record low in September. Over the past four reported quarters, Amazon, Alphabet, Microsoft and Meta spent more than $600 billion on capital expenditures, while Apple spent about $10 billion. Apple still faces pressure from higher memory chip costs, which Bank of America says will weigh on iPhone margins, and the bank considers Wall Street's margin forecasts too high into next year.
- Inuvo's IntentKey Puts Custom Audiences Live on Safari and iPhone Within 24 Hours
Inuvo (NYSE American: INUV) says its managed IntentKey service can put custom audiences live on Safari and iPhone within 24 hours of an approved campaign plan. Since Apple's iOS 27 update further limited how advertisers recognize people in Safari, the company says IntentKey has kept the same share of iPhone impressions with no change in client performance. Unlike cookie-based approaches, IntentKey uses a large language model to read content across the open web and infer interest and intent, with no cookies or personal data attached to profiles. Roughly a third of its iPhone traffic now runs on iOS 27, and Inuvo notes it first offered Safari reach without cookies in 2022 and again in 2023 when Apple tightened tracking in iOS 17.
- Gold Has Cooled From Its First-Quarter Record, Yet Miners Still Sold Ounces at Prices More Than 20% Above Last Year
Gold's third-quarter average was $4,262 an ounce, about 23% above the same quarter of 2025, but it has fallen for two straight quarters from a first-quarter record of $4,872.90. The LBMA Gold Price PM was $3,913.25 on October 30. The World Gold Council linked September's decline to rising Treasury yields and the U.S. dollar after the Fed's rate increase, though the 10-year yield has since eased from 5.29% to 4.94%. Buying has held up, with gold-backed ETFs taking in a record $31 billion in the third quarter and central banks buying 289 tonnes in the second quarter. Four gold miners reported realized prices more than 20% above a year earlier.
- Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More
Wall Street analysts made several rating changes on Monday, November 2, 2026, after the Nasdaq fell 5.2% in October. Upgrades include Amazon.com to Buy from Accumulate at Phillip Securities, with its target raised to $330 from $320, and CrowdStrike to Buy from Hold at Deutsche Bank, with its target lifted to $300 from $240. Morgan Stanley downgraded Coinbase Global to Underweight from Equal Weight and cut its target to $120 from $258, while Loop Capital cut Reddit to Hold from Buy with a target of $100 from $250. Among initiations and resumptions, TD Cowen started AngloGold Ashanti at Buy with a $123 target, and Morgan Stanley resumed L3Harris Technologies at Overweight with a $402 target.
- SuperMatics Is Building AI to Find the Next Superconductors for Commercial Wire
SuperMatics, a Berkeley company building AI exclusively for superconductors, argues that the gap lies not in discovering materials but in making tough, affordable wire. It points to rising demand from AI data centers and fusion developers, which rely on costly, scarce high-temperature superconducting tape. Its models, built on physics including the Modulated Electron Lattice (MEL) framework, predict properties, write synthesis recipes and simulate finished wire, and every result, failures included, retrains them. The company works with researchers at UC Berkeley and Georgia Tech and is in talks with materials and technology firms on joint programs. It will present at the Plug and Play Silicon Valley November Summit on November 5.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.